Adaptative Patient-Comfort Nozzle
GentleMist Technology™, No burn - No pain Nozzle
The Solution to Pain-Free Intranasal Medication
Introducing GentleMist Technology™, the newly engineered and improved nozzle, exclusively designed by Dr. Ferrer BioPharma to deliver the right doses of medication without generating excessive pressure against the nasal mucosa. This innovative nozzle technology eliminates the side effects of pain and burning commonly associated with commercially available nasal sprays on the market, making it the perfect choice for those who are sensitive to these sensations.
The GentleMist Technology™ nozzle is specially designed to deliver a fine mist that coats the nasal passages, ensuring that the medication is effectively absorbed without causing discomfort. This makes it easy to administer, even for those with sensitive nasal passages.
The nozzle also has a unique locking mechanism that prevents accidental discharge of the medication, ensuring that it is only used when needed. The nozzle is made with high-grade materials and is designed to be easy to clean and maintain, making it a hygienic and long-lasting solution.
In short, the GentleMist Technology™ is a game-changer in the field of intranasal medication delivery, providing a pain-free, easy-to-use, and effective solution for the treatment of various respiratory conditions. ClorNasal, and other intranasal products developed by Dr. Ferrer BioPharma come with this improved nozzle and provide an unmatched user experience.
Eliminates pain and discomfort
Distributes appropriate dosage using the correct angle for no dripping
Exceptional for vaccine and biologics delivery
Beneficial for patients on oxygen, nosebleeds, and irritated mucosa
80% of wound infections traced by DNA to bacteria in the patients' own nose
Approximately 60 million Americans suffer from allergies each year, making it the 6th leading cause of chronic illness in the country.
Intranasal corticosteroids are the most effective treatments for allergic rhinitis, providing relief for up to 80% of patients.